The objective of this program is to provide GaM for compassionate use in patients withrelapsed/refractory histologic or molecular glioblastoma who have exhausted availabletreatments.The population of this program is adult patients aged greater than or equal to 18 yearswith a diagnosis of relapsed/refractory histologic or molecular glioblastoma, accordingto the WHO 2021 diagnostic criteria.Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic gliomain adults if there is microvascular proliferation or necrosis or TERT promoter mutationor EGFR gene amplification or +7/-10 chromosome copy number changes
